Zobrazeno 1 - 10
of 77
pro vyhledávání: '"Bulent Arman Aksoy"'
Publikováno v:
BMC Bioinformatics, Vol 20, Iss 1, Pp 1-13 (2019)
Abstract Background Multiplexed in-situ fluorescent imaging offers several advantages over single-cell assays that do not preserve the spatial characteristics of biological samples. This spatial information, in addition to morphological properties an
Externí odkaz:
https://doaj.org/article/c64d3bb8706d407089639aeb14d6fd98
Autor:
Alex Rubinsteyn, Julia Kodysh, Isaac Hodes, Sebastien Mondet, Bulent Arman Aksoy, John P. Finnigan, Nina Bhardwaj, Jeffrey Hammerbacher
Publikováno v:
Frontiers in Immunology, Vol 8 (2018)
This paper describes the sequencing protocol and computational pipeline for the PGV-001 personalized vaccine trial. PGV-001 is a therapeutic peptide vaccine targeting neoantigens identified from patient tumor samples. Peptides are selected by a compu
Externí odkaz:
https://doaj.org/article/5976529a96fd4d6c9419a82fea91d16e
Autor:
Jacob S. Bowers, Kinga Majchrzak, Michelle H. Nelson, Bulent Arman Aksoy, Megan M. Wyatt, Aubrey S. Smith, Stefanie R. Bailey, Lillian R. Neal, Jeffrey E. Hammerbacher, Chrystal M. Paulos
Publikováno v:
Frontiers in Immunology, Vol 8 (2017)
Phosphatidylinositol-3-kinase p110δ (PI3Kδ) inhibition by Idelalisib (CAL-101) in hematological malignancies directly induces apoptosis in cancer cells and disrupts immunological tolerance by depleting regulatory T cells. Yet, little is known about
Externí odkaz:
https://doaj.org/article/692b7233642b4e4695b1d1a1960096eb
Autor:
Alexandra Snyder, Tavi Nathanson, Samuel A Funt, Arun Ahuja, Jacqueline Buros Novik, Matthew D Hellmann, Eliza Chang, Bulent Arman Aksoy, Hikmat Al-Ahmadie, Erik Yusko, Marissa Vignali, Sharon Benzeno, Mariel Boyd, Meredith Moran, Gopa Iyer, Harlan S Robins, Elaine R Mardis, Taha Merghoub, Jeff Hammerbacher, Jonathan E Rosenberg, Dean F Bajorin
Publikováno v:
PLoS Medicine, Vol 14, Iss 5, p e1002309 (2017)
BACKGROUND:Inhibition of programmed death-ligand 1 (PD-L1) with atezolizumab can induce durable clinical benefit (DCB) in patients with metastatic urothelial cancers, including complete remissions in patients with chemotherapy refractory disease. Alt
Externí odkaz:
https://doaj.org/article/dce1a7888e3c4bdeb85b68605ddcef52
Autor:
Jeff Hammerbacher, Alexandra Snyder, Jedd D. Wolchok, Taha Merghoub, Eliezer Van Allen, Diana Miao, Matthew D. Hellmann, Bulent Arman Aksoy, Alexander Rubinsteyn, Arun Ahuja, Tavi Nathanson
Immune checkpoint inhibitors are promising treatments for patients with a variety of malignancies. Toward understanding the determinants of response to immune checkpoint inhibitors, it was previously demonstrated that the presence of somatic mutation
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8c383047995adabf8167b417de457d83
https://doi.org/10.1158/2326-6066.c.6548920.v1
https://doi.org/10.1158/2326-6066.c.6548920.v1
Autor:
Erica L. Stone, Qin Liu, Tara C. Mitchell, Lynn M. Schuchter, Mark P. Rubinstein, Jeff Hammerbacher, Mary Jo Turk, Brian Nam, Ravi K. Amaravadi, Giorgos C. Karakousis, Xiaowei Xu, Xiangfan Yin, Cathy Zheng, Wei Xu, Bulent Arman Aksoy, Tamer B. Shabaneh, Jenna R. Karras, Erin M. O’Brien, Emilio Sanseviero
Supplementary Figure 2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5748cb60e9e7c0ed600dceb8778ece8c
https://doi.org/10.1158/2326-6066.22539752
https://doi.org/10.1158/2326-6066.22539752
Autor:
Erica L. Stone, Qin Liu, Tara C. Mitchell, Lynn M. Schuchter, Mark P. Rubinstein, Jeff Hammerbacher, Mary Jo Turk, Brian Nam, Ravi K. Amaravadi, Giorgos C. Karakousis, Xiaowei Xu, Xiangfan Yin, Cathy Zheng, Wei Xu, Bulent Arman Aksoy, Tamer B. Shabaneh, Jenna R. Karras, Erin M. O’Brien, Emilio Sanseviero
Supplementary Figure Legends for S1-4
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::625911bc84818c026b86351efd53ba96
https://doi.org/10.1158/2326-6066.22539743.v1
https://doi.org/10.1158/2326-6066.22539743.v1
Autor:
Erica L. Stone, Qin Liu, Tara C. Mitchell, Lynn M. Schuchter, Mark P. Rubinstein, Jeff Hammerbacher, Mary Jo Turk, Brian Nam, Ravi K. Amaravadi, Giorgos C. Karakousis, Xiaowei Xu, Xiangfan Yin, Cathy Zheng, Wei Xu, Bulent Arman Aksoy, Tamer B. Shabaneh, Jenna R. Karras, Erin M. O’Brien, Emilio Sanseviero
Supplementary Figure 4
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::614ede95e77a92970fddcabd0e7b8783
https://doi.org/10.1158/2326-6066.22539746.v1
https://doi.org/10.1158/2326-6066.22539746.v1
Autor:
Jeff Hammerbacher, Alexandra Snyder, Jedd D. Wolchok, Taha Merghoub, Eliezer Van Allen, Diana Miao, Matthew D. Hellmann, Bulent Arman Aksoy, Alexander Rubinsteyn, Arun Ahuja, Tavi Nathanson
1. Mutation burden and survival using updated mutation calling system. 2. Similarity scores between samples and viral or non-viral epitopes. 3. Deconvolution of immune infiltrates. 4. Gene set enrichment analysis.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c2e63b676846a8cb37b6df340ee7089b
https://doi.org/10.1158/2326-6066.22538866
https://doi.org/10.1158/2326-6066.22538866
Autor:
Erica L. Stone, Qin Liu, Tara C. Mitchell, Lynn M. Schuchter, Mark P. Rubinstein, Jeff Hammerbacher, Mary Jo Turk, Brian Nam, Ravi K. Amaravadi, Giorgos C. Karakousis, Xiaowei Xu, Xiangfan Yin, Cathy Zheng, Wei Xu, Bulent Arman Aksoy, Tamer B. Shabaneh, Jenna R. Karras, Erin M. O’Brien, Emilio Sanseviero
Antibodies targeting CTLA-4 induce durable responses in some patients with melanoma and are being tested in a variety of human cancers. However, these therapies are ineffective for a majority of patients across tumor types. Further understanding the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::047be4960c8f661fd3915c70c3ec0d81
https://doi.org/10.1158/2326-6066.c.6549173.v1
https://doi.org/10.1158/2326-6066.c.6549173.v1